The most frequent cause of fatal events with CTLA-4 inhibitors was colitis, while pneumonitis, hepatitis, and neurotoxic adverse effects were most likely associated with fatal events with PD-1/PD-L1 inhibitors [13]. This evidence concerns the gene CD274 and colitis.